Clik here to view.
Oral REVLIMID® Plus Dexamethasone Granted Approval for Treatment of Patients...
BOUDRY, Switzerland & TOKYO Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that REVLIMID® (lenalidomide), a cancer medicine that is...
View ArticleClik here to view.
AGC Earns The Skin Cancer Foundation’s Seal of Recommendation for Automotive...
TOKYO AGC, a world-leading manufacturer of glass, chemicals and high-tech materials, announced that it has earned The Skin Cancer Foundation’s Seal of Recommendation, an international symbol of safe...
View ArticleClik here to view.
Blue Belt Technologies Announces the First Robotics-Assisted Partial Knee...
MINNEAPOLIS Blue Belt Technologies, a medical technology company specializing in robotic solutions for orthopedic surgery, announced the first Navio-assisted surgery performed in Australia utilizing...
View ArticleClik here to view.
Duke University Delegation Visits NCKU to Foster Partnership for Ventricular...
TAINAN, Taiwan Dr. Carmelo Alessio Milano, the Surgical Director for Heart Transplant and LAVD Program, from Duke University School of Medicine, United States, led a delegation to visit National...
View ArticleClik here to view.
NCKU, Duke Collaborate to Better Design a Ventricular Assist Device
TAINAN, Taiwan A workshop involving doctors and researchers from National Cheng Kung University (NCKU) and Duke University School of Medicine was held on the morning of December 22 at the Heart...
View ArticleClik here to view.
V-Line Lifting, vs. Gravity and Time
SEOUL, South Korea In the recent years, Lifting by threads or laser and simple procedures such as fillers or Botox are becoming more popular to maintain youth and look younger. Types of threads used...
View ArticleClik here to view.
Cheekbone Reduction Surgery to Make Slim Face Shape from the Front and Side
SEOUL, South Korea A slim face shape is an element to look young and a condition for beauty. Even when having the same face size, if the cheekbone or square jaw are developed excessively, one’s face...
View ArticleClik here to view.
ReproCELL Announced: A Joint Development with the National Cancer Center
YOKOHAMA, Japan ReproCELL, Inc. (JASDAQ:4978): “ReproHP Medium,” a highly functional culture fluid for human primary liver cells developed in conjunction with the National Cancer Center, is set to...
View ArticleClik here to view.
Clik here to view.
Takeda Provides Further Information about Its New Business Venture with Teva
OSAKA, Japan & JERUSALEM Takeda Pharmaceutical Company Limited (TOKYO: 4502) and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) (TASE: TEVA) today made the below follow-up announcement...
View ArticleClik here to view.
日本における武田薬品とテバ社による合弁会社の追加情報の公表について
大阪 & イスラエル・エルサレム （ビジネスワイヤ） — 武田薬品工業株式会社（本社：大阪市中央区、以下「武田薬品」）とTeva Pharmaceutical Industries Ltd. （本社：イスラエル...
View ArticleClik here to view.
訂正・差し替え 日本における武田薬品とテバ社による合弁会社の追加情報の公表について
大阪 & イスラエル・エルサレム （ビジネスワイヤ） — 武田薬品工業株式会社（本社：大阪市中央区、以下「武田薬品」）とTeva Pharmaceutical Industries Ltd. （本社：イスラエル...
View ArticleClik here to view.
CORRECTING and REPLACING Takeda Provides Further Information about Its New...
OSAKA, Japan & JERUSALEM Insert after fifth paragraph, first sentence of release: The new business venture will be instantly accretive to Teva’s non GAAP EPS in 2016 and beyond. This Smart News...
View ArticleClik here to view.
武田就与Teva建立新企业事宜披露更多信息
日本大阪和与耶路撒冷 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited)(TOKYO: 4502)与Teva Pharmaceutical Industries Ltd. (NYSE: TEVA)(TASE:...
View ArticleClik here to view.
Novocure Submits PMA Partial Amendment Application to Japanese...
ST. HELIER, Jersey Novocure (NASDAQ: NVCR) announced today that it submitted a premarket approval (PMA) partial amendment application to the Japanese Pharmaceuticals and Medical Devices Agency...
View ArticleClik here to view.
武田薬品: 第34回J.P.モルガン・ヘルスケア・カンファレンスでのプレゼンテーションについて
大阪 （ビジネスワイヤ） — 米国太平洋標準時2016年1月11日から14日にかけて米国カリフォルニア州サンフランシスコで開催される、第34回J.P.モルガン・ヘルスケア・カンファレンスにて、同1月12日、当社代表取締役社長ＣＥＯのクリストフ・ウェバーがプレゼンテーションを行いますので、発表資料および音声の配信の詳細について、下記の通りお知らせします。 記 日 時...
View ArticleClik here to view.
Takeda to Present at the 34th Annual J.P. Morgan Healthcare Conference
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO: 4502) (“Takeda”) today announced that Christophe Weber, President and Chief Executive Officer of Takeda, will make a formal presentation on...
View ArticleClik here to view.
武田将在J.P. Morgan医疗保健会议第34届年会上呈报
日本大阪 (美国商业资讯) –武田药品工业株式会社(TOKYO: 4502)（“武田”）今天宣布，武田总裁兼首席执行官Christophe Weber将于当地时间1月12日在加州旧金山召开的J.P. Morgan医疗保健会议第34届年会上进行一场正式呈报。该呈报之后将是问答专场。 时间安排的细节、网络直播音频和呈报材料的访问方法如下： 日期和时间 1月12日星期二，上午11:30 –...
View ArticleClik here to view.
エリテックが急性骨髄性白血病を対象とした第2b相試験のDSMBによる第3回安全性評価と試験継続を発表
仏リヨン （ビジネスワイヤ） — 急性白血病および医療ニーズが満たされていないその他の腫瘍適応症を対象に革新的な「腫瘍飢餓化」治療薬の開発に当たっているフランスのバイオ製薬企業エリテック・ファーマ（Paris:ERYP）（ADR:EYRYY）（Euronext Paris: FR0011471135 –...
View ArticleClik here to view.
EYE TECH CARE宣布与中国投资者达成一项重要的注资和伙伴关系协议
法国里昂 (美国商业资讯) — EYE TECH CARE SA是一家开发和营销青光眼无创治疗眼科医疗器材的公司，该公司今天宣布已获得一家中国投资者的新一轮注资。恒松资本将分两轮投资，总金额约为2500万欧元，并将支持EYE TECH CARE的国际扩张。公司将受益于恒松资本在中国的布局，从而推进已经于2015年启动的产品报批。...
View Article